Key Metrics
1.7
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
Q3
Health Policy
SJR
- Q3 Health Policy
- Q3 Pharmacology (medical)
- Q2 Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
0.3
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Indexed in the following public directories
-
Web of Science -
Scopus -
SJR
Topics Covered
- Stargardt disease
- Rare disease
- Rituximab
- Quality of life
- Rare cancer
- Immunotherapy
- Hematopoietic stem cell transplantation
- Treatment options
- Orphan drug
- Adrenal insufficiency
- Cystic fibrosis
- Symptom burden
- Biliary cirrhosis
- Chagas disease
- Choroideremia
- Eculizumab
- Liver transplantation
- Gene replacement
- Antisense oligonucleotides
Journal Specifications
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2013 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Expert Opinion on Orphan Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022
- 31 Dec 24
- Expert Opinion on Orphan Drugs
-
Full paper
Current and emerging therapies for the treatment of leishmaniasis
- 31 Dec 24
- Expert Opinion on Orphan Drugs
-
Full paper
Emerging therapies against Naegleria fowleri
- 31 Jul 24
- Expert Opinion on Orphan Drugs
-
Full paper
Management of pulmonary hypertension in infants
- 27 Jul 24
- Expert Opinion on Orphan Drugs
-
Full paper
Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listing
- 3 Feb 24
- Expert Opinion on Orphan Drugs
-
Full paper
Overview of genetic testing in Prader-Willi syndrome
- 23 Sep 23
- Expert Opinion on Orphan Drugs
Scite analysis
Powered by scite_
862 articles received 4k citations see all
- 55 Supporting
- 3,768 Mentioning
- 1 Contrasting
Editorial notices
- 2 Retractions
- 0 Withdrawals
- 7 Corrections
- 0 Errata
- 0 Expression of Concern
FAQs
How long has Expert Opinion on Orphan Drugs been actively publishing?
Expert Opinion on Orphan Drugs has been in operation since 2013 till date.
What is the publishing frequency of Expert Opinion on Orphan Drugs ?
Expert Opinion on Orphan Drugs published with a Monthly frequency.
How many articles did Expert Opinion on Orphan Drugs publish last years ?
In 2023, Expert Opinion on Orphan Drugs published 3 articles.
What is the eISSN & pISSN for Expert Opinion on Orphan Drugs ?
For Expert Opinion on Orphan Drugs,eISSN is 2167-8707 and pISSN is2167-8707.
What is Citescore for Expert Opinion on Orphan Drugs ?
Citescore for Expert Opinion on Orphan Drugs is 1.7.
What is SNIP score for Expert Opinion on Orphan Drugs ?
SNIP score for Expert Opinion on Orphan Drugs is 0.3.
What is the SJR for Expert Opinion on Orphan Drugs ?
SJR for Expert Opinion on Orphan Drugs is Q3.
Who is the publisher of Expert Opinion on Orphan Drugs ?
TAYLOR & FRANCIS LTD is the publisher of Expert Opinion on Orphan Drugs.